Effect of Once-Weekly Exenatide in Patients With Type 2 Diabetes Mellitus With and Without Heart Failure and Heart Failure–Related Outcomes
Marat Fudim(Clinical Research Institute), Robert J. Mentz(Duke University), Renato D. Lópes(Duke University), Jennifer A. White(Clinical Research Institute), Julio Wainstein(Wolfson Medical Center), Neha J. Pagidipati(Duke University), Barry Reicher(AstraZeneca (Netherlands)), Yuliya Lokhnygina(Clinical Research Institute), Nayyar Iqbal(Chinese University of Hong Kong), Ján Murín(University Hospital Bratislava), Adrian F. Hernandez(Duke University), Peter Öhman(Chinese University of Hong Kong), Rury R. Holman(University of Oxford)
Cited by 95
Related Papers
2023 Focused Update of the 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
|European Heart Journal|2023|2.2k
Effects of Once-Weekly Exenatide on Cardiovascular Outcomes in Type 2 Diabetes
|New England Journal of Medicine|2017|2.1k
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial
|The Lancet|2018|1.8k
Telehealth transformation: COVID-19 and the rise of virtual care
|Journal of the American Medical Informatics Association|2020|1.6k
Medical Therapy for Heart Failure With Reduced Ejection Fraction
|Journal of the American College of Cardiology|2018|1.3k